We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · May 24, 2016

Elderly Patient With RCC

Written by
Andrew Fintel DO

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • rajeev vijayakumar

    Thank you for the case. In our practice in India, we prefer Pazopanib 400 mg od to start of initially and rise it to 800 mg if patient tolerates it. Sunitinib at 25 mg od two week on and 1 week off can also be given. We need to monitor LFT and TSH regularly


  • navdeep singh

    Sorafenib is better tolerated. Start with 200 mg bd .. Then escalate...


  • Annalisa Bramati

    I agree with both pazopanib starting 400 mg die or sunitinib 25 mg die 2 week on/ 1 week off, following the patient with our multidisciplinary team of cardiologist.


  • Oct 31, 2020

    Pending Moderator approval.
    Delete

Further Reading